Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Hawk, thanks. You called it Hart-Nash, and the TRRC approved a Nash-Murphy #1, so it's probably the Nash-Murphy. We'll find out soon enough ... it doesn't matter so long as they are drilling! Good luck Hawk.
Hawk, I'm a little confused on drilling timelines...
In post #8316 you wrote "Spud of the Hart-Nash well. This well should reach TD in a few weeks, since they will now be drilling 24/7, and all the weak parts were replaced on the Phantom #1 drilling rig."
In this latest post you wrote "I have heard 10 days to TD on this vertical being currently drilled, by someone else with experience and knowledge in the patch."
Maybe they are different wells. In the 4/21 PR they said "the Phantom I has moved to a second well on the Palo Pinto 12 well project on a location with a Ellenberger or a Mississippi reef high". Then in the 5/2 PR they said "Phantom Rig I has commenced drilling on the Murphy #3".
I'm obviously confused. Help me out if you can. TIA.
Hart #8 "will be put into production" (PR)...
Doesn't this mean they know the flow rates, or at least they know this well is commercially viable?
I don't see why we are down, if my inference is correct.
Jgbuz, WHAT WOULD IT TAKE TO MAKE TRBY MORE PROFITABLE ?
Please read my earlier posts about branding and brand managment. The picture here is so confused. IMO it is the #1 reason for failure.
2.17 Thurs, 1.93 now ... what gives?
Last summer Bend Arch was reworking the Nash 1-C Barnett Shale well. I don't believe we ever got an update on production numbers, did we?
Thanks BSD! Outstanding news! CB ROCKS!
Thanks BSD! But what does it mean?
Is this the current situation, or earlier?
"Hart # 8 initial test after being acidized and fracture stimulated."
"The well still has 170 barrels of water (7,224 gallons) from the frac job in the formation that will have to be removed before full potential of the well can be realized. The water acts as a weight on the formation that the gas has to overcome before it can rise to the surface. Currently the well pressure is 600 PSI and should continue to rise as the weight of the water is removed. Due to the sever drought in the area and the extreme risk of grass fire the test was conducted with the smallest choke that we had available. The choke that we used was a 1/8” orifice which is a slightly bigger then the diameter of a pencil lead used in a typical # 2 pencil that you probably have on your desk. "
ThSeeker: "NET SHARE VALUE"
Did you mean NET ASSET VALUE? Thanks for your informative posts.
Oil closed above $70 for first time /em
MMs have taken it down to mid-6s /em
By the 15th calendar day after originally due...
which was March 31. That would be Saturday and I don't know if companies file on weekends, even though the SEC rule says calendar day.
That's certainly true, wonway /em
Is bad news behind the delay?
I'm beginning to feel that bad news, like a dry hole or more likely an uncomercially viable well, is behind the delay in releasing news about the Hart #8 well. I hope I'm wrong, but this seems like a huge delay. I can't imagine that they'd be holding back terrific news just to put it in the 10K.
Information on flow rates does seem overdue...
given the 4-7 day estimate to extract the water, doesn't it?
Lowfloat, I appreciate your analytical posts /em.
Yes, at 2:30pm all of RB still seems down.
Cutting corners, re: commercial...
I'd like drillbit or hawk to weigh in on this, but I believe this is a single-zone completion. If the gas flow is not economically viable, couldn't they do a multiple-zone completion to one or more of the other four potential pay zones?
Hawk, the Hart #8 well has five potential O&NG formations. Did they perforate and frac only the lowest one in the Strawn Sand? If they did, why would you think they did that?
By the way, did you notice the PR headline called it the "Hart #1 Natural Gas Well"?
Sometime, long ago, Bill Jacobson said he thought this would be a $4 stock. Do folks here think that's likely?
Barneey, I know Hawk and I believe in him. If CB/JC are keeping quiet until there is significant news to release, I'd think Hawk would also wait for news to post. That said, I cannot confirm either way ... just my belief in his extraordinary DD and knowledge that he has been adding all along the way.
Oopps - got it. I was filtering replies to ignored.
Why do I have huge gaps between messages, only on the AMEP board? One example: the message number skips twenty messages.
NG continues to slide... Apr futures 6.53
http://futures.tradingcharts.com/marketquotes/NG.html
Thanks contractor (eom).
I don't show a 6203, Slip. My posts skip from 6200 to 6207, which I've assumed are deleted. When I click on the link you posted, it brings up Heyjoe's post. I have no browser troubles on RB or (to my knowledge) on other Ihub boards.
Where is SlipperyWing's BDC post? The board's protectors are deleting so many posts that they may delete some wrong ones and cause erratic retrieval of others.
Contractor, good article on Barnett non-core areas.
Reinforces prospects for AMEP on its leases. Read on about use of horizontal drilling to reduce chances of water from below the formation.
uw86- I'm a shareholder and am not bashing...
But would you take a few minutes to present your case for optimism here? I and probably some others here would appreciate it. TIA.
New feature on RB: read-only! What a cracker-jack tech support team!!!
Same here, X. But you know, it's the weekend and RB support probably didn't want their weekend ruined by going in to work. So I'm sure they will look into it on Monday.
Article from today's Rochester fish wrapper about the University of Rochester's research into use of stem cells to heal damaged hearts.
Remember MW's discussions about licensing pharma companies to deliver drugs and stem cells directly to the myocardium through the MYO-VAD.
Remember also my post last summer about finding the U of R has consolidated its Center for Cardiovascular Research right around the corner from Biophan's headquarters, and that Center's Director is on the Biophan scientific advisory board.
The two buildings are probably about 500 yards apart, as the crow flies.
I can now report my finding of guarded tunnels connecting the two facilities, and leading to a shared super-secret underground research lab.
Just kidding about that.
http://www.rochesterdandc.com/apps/pbcs.dll/article?AID=/20060122/NEWS01/601220336&template=prin...
January 22, 2006
UR tests whether stem cells can heal hearts
Scientists hope adult donors' cells repair scars after attack
Lauren Stanforth
Staff writer
For the first time, the University of Rochester is testing adult stem cells in patients to see whether the cells can actually repair an organ.
UR is one of 17 sites in the United States that are embarking on a ground-breaking study investigating whether an injection of stem cells into the blood can actually reduce scarring in the heart of someone who just had a heart attack.
It's believed to be the first clinical trial in the United States to test how stem cells taken from adult volunteers might help restore heart function in someone else. Stem cells are the building blocks for the organs and tissues in the body.
"It's kind of a landmark trial," said Dr. Joshua Hare, lead investigator of the study and professor of medicine in the cardiology division at Johns Hopkins University in Baltimore.
The stem cell that will be used is a specific kind of cell, called mesenchymal (pronounced mess-IN-kimal), that is found in a person's bone marrow and gives rise to bone, cartilage and muscle cells. Researchers across the country also are working with stem cells derived from other parts of the body, such as the brain, to possibly one day treat Parkinson's and Alzheimer's diseases.
The drug company that's paying for the study, Osiris Therapeutics in Baltimore, says it gets the bone marrow-derived cells from adult volunteers. One of Osiris' founders, Dr. Arnold Caplan, discovered the mesenchymal stem cell while doing research at Case Western Reserve University in Cleveland. He helped found the drug company in 1992.
Osiris received approval from the U.S. Food and Drug Administration to conduct a clinical trial in which the stem cells are given intravenously to a person who has had a heart attack at most 10 days earlier.
When a heart attack occurs, blood is blocked from providing oxygen to various parts of the heart. Those areas can become damaged because of the lack of oxygen and can lead to weaker pumping and eventually congestive heart failure. The hope is that the stem cells will home in on the injured heart muscle, become heart cells themselves and repair the muscle damage.
This Phase I trial's first aim is to test the stem cells' safety in varying doses in different patients. The body won't reject the stem cells because the cells haven't developed properties, such as a blood type, that would identify them with one body over another.
But patients' hearts will also be monitored for up to two years to see whether scarring has decreased. The trial will be small, with only 48 patients enrolled nationwide. At the University of Rochester, about six people will be recruited. No side effects are expected, but researchers will test organ function and watch for any signs of infection after the stem cells are given.
If safety is proved, hundreds of people will be enrolled in a Phase II trial in the United States to attempt to prove that the therapy works.
"Ideally, these stem cells would take residence in the heart and become heart cells," said Dr. Craig Narins, the University of Rochester Medical Center cardiologist leading the study here. "You're trying to get new muscle to grow."
The University of Rochester has had researchers working with bone marrow stem cells to treat leukemia and lymphoma for years. Other researchers are using animals to determine how stem cells might help brain and nervous system disorders.
But other than for blood cancers, this is the first time UR has tested stem cells in people, said Dr. Howard Federoff, senior associate dean for basic research at the UR Medical Center.
Despite the excitement surrounding new stem cell research in humans, researchers stress caution about jumping to conclusions about their success.
Although studies in animals have shown that mesenchymal stem cells can find their way to the injured heart through the bloodstream, it's not known exactly why they do that, Narins said.
Also, two similar studies were done in Europe, in which many of the stem cells found in a person's bone marrow were used to determine their curative properties. In one study, the heart had better pumping function. In another, the treatment had no effect.
Dr. Robert Robbins, director of Stanford University's Cardiovascular Institute, said he's not convinced that these stem cells taken from adults will result in the kind of heart muscle repair that's needed.
Robbins said that for significant muscle growth, one would need stem cells cultivated from embryos — the kind of research that has sparked controversy nationwide.
Embryonic research involves taking an embryo that is only a few days old and cultivating stem cells out of it, destroying it in the process.
Those in favor of the research say embryonic stem cells can develop into any tissues of the body and can replicate in large quantities. Those against embryonic research find it morally reprehensible to kill an embryo to harvest the cells.
The federal government has banned federal research funding on new embryonic stem cell lines since 2001 — thus putting a halt to much of that research.
Congress is expected to take up the debate about funding embryonic research this year. The New York state Assembly this month passed legislation to create the state's own stem cell institute — a lobbying effort by the University of Rochester and downstate research institutions to compete with California and New Jersey, states currently funding stem cell research on their own. It's unknown if or when the state Senate will take up the matter.
Still, the use of stem cells as a regular part of therapy is years away, researchers say.
"There's this massive media hype," Robbins said. "But ... it's usually a product development life of 20 years."
LSTANFOR@DemocratandChronicle.com
Apologies, Board, for my bad-language post last nite expressing my anger at Raging Bull for the latest extended outage. Their tech team could never support a real business. They probably said "Oh its the weekend, we'll look into it Monday".
Young bub,
I think it is. Might be worth a couple of speculative bucks, don't you think?
What's it been? Maybe two years since we've talked a little about O&G businesses?
One thing I have realized over time: you are REALLY in the bidness. I am speculating; but with your help, and with Hawk's help, I also am learning. Thanks, my friend .
That G-D F-ing RB, you couldn't EVER run a business that way! Total TRASH. A-H techs. Just F-ing unbelievable POS's.
OT Off the top of my head, I believe the NRIs are the standard around 75% after the owners overriding royalty (or whatever that is called).
Bub, I doubt Nasdaq is our first stop...
$4.00 share price requirement is pretty formidable. Unless mgmt. totally screws up the AMEX application process, we languish/rot on the OTC-BB for several more years, then maybe Nasdaq first or never. LOL.
OT Looks like all of RB is down AGAIN.
OT Looks like all of RB is down AGAIN.
OT Looks like all of RB is down AGAIN.